Subsequently, in a randomized,placebo-controlled, phase III trial it was demonstrated the efficacy and safetyof niraparib as maintenance treatment in a broad population of patients withplatinum-sensitive, recurrent ovarian cancer, regardless of the presence orabsence of BRCA1, BRCA2 mutations or HRdeficiency status (Mirza etal., 2016). Here, BRCA2 is linked to ovarian carcinoma.